A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease | MicrobiomeTrials← Back to trialsNCT06807463
A Trial to Assess the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2025-03-31Est. Completion: 2026-09-15
Enrollment target: 50 participants Locations- Teva Investigational Site 12138, Murrieta, California, United States
- Teva Investigational Site 12131, Colorado Springs, Colorado, United States
- Teva Investigational Site 12134, Inverness, Florida, United States
- Teva Investigational Site 12126, Miami Lakes, Florida, United States
- Teva Investigational Site 12135, New Port Richey, Florida, United States
- Teva Investigational Site 12130, Atlanta, Georgia, United States
- Teva Investigational Site 12133, Marrero, Louisiana, United States
- Teva Investigational Site 12132, Clinton Township, Michigan, United States
- Teva Investigational Site 12121, Wyoming, Michigan, United States
- Teva Investigational Site 12129, Rochester, Minnesota, United States
- Teva Investigational Site 12128, New York, New York, United States
- Teva Investigational Site 12125, Greenville, North Carolina, United States
- Teva Investigational Site 12127, Winston-Salem, North Carolina, United States
- Teva Investigational Site 12137, Waco, Texas, United States
- Teva Investigational Site 12122, Ogden, Utah, United States
Other microbiome trials you might be interested in
Lipid Metabolism DisordersLipid Metabolism, Inborn ErrorsCongenital Heart DiseaseInflammatory Bowel Disease (IBD)Rheumatic DiseasesCeliac Disease in ChildrenCeliac Disease in Adolescents
Preventive measures are increasingly coming to the forefront of medicine. Many of these measures can be implemented as e…
Jena, GermanyEst. completion Jan 31, 2027
Celiac Disease
The purpose of this clinical study is to learn more about celiac disease pathogenesis and clinical symptoms. In particul…
Teva Investigational Site 12123, Lynchburg, Virginia, United StatesTeva Investigational Site 78139, Fitzroy, AustraliaTeva Investigational Site 78140, Maroochydore, AustraliaTeva Investigational Site 78137, Midland, AustraliaTeva Investigational Site 40063, Helsinki, FinlandTeva Investigational Site 40062, Tampere, FinlandPasadena, United StatesEst. completion May 1, 2027